MedinCell SAEURONEXT: MEDCL

Medincell Appoints Edna Venneker, MD, as Chief Medical Officer

· Issued by MedinCell SA via Business Wire

Summary by 6ix AI

Medincell, a clinical- and commercial-stage biopharmaceutical licensing company listed on Euronext (MEDCL) that develops long-acting injectable treatments, has appointed Edna Venneker, MD, as Chief Medical Officer.

Key details

  • Edna Venneker most recently served as Head of Development and Senior Vice President at Grünenthal, where she oversaw areas including clinical development, clinical operations and data science; she also served there as Deputy Chief Medical Officer.
  • She has dealt directly with the FDA (US Food and Drug Administration), EMA (European Medicines Agency) and PMDA (Japan's Pharmaceuticals and Medical Devices Agency) across the drug development lifecycle.

6ix AI wrote this summary from the release below and checked it against the release.

Experienced international pharmaceutical executive with a strong track record in clinical development, regulatory strategy, program execution and portfolio leadership

Former Head of Development and Senior Vice President at Grünenthal, with broad drug development experience across multiple therapeutic areas, including deep expertise in neuroscience and CNS disorders

MONTPELLIER, France, September 01, 2026--(BUSINESS WIRE)--Medincell (Euronext: MEDCL), a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas, today announced the appointment of Edna Venneker, MD, as Chief Medical Officer.

Edna Venneker brings extensive international experience in drug development, spanning non-clinical and clinical strategy, regulatory affairs, program execution and portfolio decision-making. Most recently, she served as Head of Development and Senior Vice President at Grünenthal, where she oversaw clinical development, clinical operations, CMC, data science including pharmacometrics and Advanced Analytics. She also served as Deputy Chief Medical Officer and as a member of the R&D Leadership Team and the R&D Portfolio Board.

Throughout her career, Edna Venneker has led global, cross-functional development programs, advised biotechnology and pharmaceutical companies on development and regulatory strategies, and interacted directly with the FDA, EMA and PMDA across the drug development lifecycle. Her experience covers a broad range of therapeutic areas and product types, including small molecules, biologics, vaccines and advanced therapies.

"For long-acting injectable medicines, medical and regulatory strategy must be embedded from the very beginning of product design. Even more so than for conventional daily medicines, their development requires the close and simultaneous integration of clinical need, pharmacology, formulation, manufacturing, usability and regulatory considerations. This makes the role of the Chief Medical Officer both central and highly cross-functional.
I look forward to working with Medincell's teams and with its current and prospective partners to evaluate opportunities, shape differentiated target product profiles and identify the most appropriate and efficient development and regulatory pathway for each program. Medincell's technology creates the opportunity to rethink how proven medicines can address important unmet needs, and I am excited to help translate that potential into meaningful new treatment options for patients," said Edna Venneker, MD, Chief Medical Officer of Medincell.

For more information, please click here: https://www.medincell.com/news/

About Medincell
medincell.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260901178231/en/

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
[email protected] / +33 (0)6 83 25 21 86

View original source (Business Wire)MedinCell SA on 6ix

Earlier from MedinCell

Later from MedinCell

All MedinCell news releases